Cord Blood News Volume 5.19 | May 16 2013

    0
    140

    Cord Blood News 5.19 May 16, 2013

         In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
    Cell Therapy News on Facebook  Cord Blood News on Twitter

    TOP STORY
    Transcription Factor Krüppel-Like Factor 2 Plays a Vital Role in Endothelial Colony Forming Cells Differentiation
    Researchers investigated the role of transcription factor Krüppel-like factor 2 in the regulation of endothelial colony forming cell (ECFC) function. Human ECFCs were isolated from cord blood and cultured. [Cardiovasc Res] Abstract

    Complimentary Wallchart: Human Hematopoietic Progenitors. Request Your Copy Today.

    PUBLICATIONS (Ranked by impact factor of the journal)

    Contribution of Bone Marrow-Derived Hematopoietic Stem/Progenitor Cells to the Generation of Donor-Marker+ Cardiomyocytes In Vivo
    Investigators aimed to identify the cell populations that can generate cardiomyocytes and to clarify whether generation of donor-marker+ cardiomyocytes requires cell fusion between bone marrow (BM)-derived cells and recipient cardiomyocytes. Purified BM stem/progenitor cells from green fluorescence protein mice were transplanted into C57BL/6 mice or cyan fluorescence protein-transgenic mice. Purified human hematopoietic stem cells from cord blood were transplanted into immune-compromised NOD/SCID/IL2rγnull mice. [PLoS One]
    Full Article

    Reduced Toxicity Conditioning and Allogeneic Stem Cell Transplantation in Adults Using Fludarabine, BCNU, Melphalan, and Antithymocyte Globulin (FBM-A): Outcomes Depend on Disease Risk Index but Not Age, Comorbidity Score, Donor Type, or HLA Mismatch
    Although reduced intensity conditioning has become standard of care for patients with hematologic malignancies undergoing allogeneic hematopoietic cell transplantation, the optimum regimen has yet to be defined, and may depend on pre-transplant patient- and/or disease-specific risk factors. Researchers report here results in 100 adults age 18-69 with high-risk hematologic malignancy who received conditioning with fludarabine, BCNU, melphalan, and rabbit FBM-A. Donors were related in 26 patients and unrelated in 74; grafts were PBSCs in 97 patients, bone marrow in two, and double cord in one. [Biol Blood Marrow Transplant] Abstract

    Endothelial Colony-Forming Cell Conditioned Media Promotes Angiogenesis In Vitro and Prevents Pulmonary Hypertension in Experimental Bronchopulmonary Dysplasia
    To determine whether human umbilical cord blood endothelial colony-forming cells (ECFCs) from preterm and term newborns have therapeutic benefit in experimental neonatal lung injury, scientists isolated cord blood ECFCs from full term and preterm newborns and prepared ECFC-conditioned media to test its therapeutic benefit on fetal pulmonary artery endothelial cell growth and function as well as alveolar type 2 cell growth. [Am J Physiol-Lung C] Abstract

    Induction of Differentiation by Down-Regulation of Nanog and Rex-1 in Cord Blood Derived Unrestricted Somatic Stem Cells
    Researchers looked upon the effects of two transcription factors Nanog and Rex-1 in self-renewal and differentiation abilities of a subpopulation of cord blood stem cells known as unrestricted somatic stem cells. [Mol Biol Rep] Abstract

    miR-146a and miR-150 Promote the Differentiation of CD133+ Cells into T-Lymphoid Lineage
    The over-expression of microRNA (miR)-146 and miR-150 has been reported during differentiation of hematopoietic stem cells into T-lymphoid lineage. Scientists evaluated the effect of their over-expression on CD133+ cells differentiation to T cells. miR-146a and miR-150 were separately and jointly transduced to human cord blood derived CD133+ cells. [Mol Biol Rep] Abstract

    Stem Cells from Umbilical Cord Wharton’s Jelly from Preterm Birth Have Neuroglial Differentiation Potential
    Researchers aimed to determine the neuroglial differentiation potential of human Wharton’s jelly-derived mesenchymal stem cells from preterm birth when compared to term delivery. [Reprod Sci] Abstract

    Gender Depended Potentiality of Differentiation of Human Umbilical Cord Mesenchymal Stem Cells into Oocyte-Like Cells In Vitro
    To clearly test the formation efficiency of oocyte-like cells from male and female human umbilical cord mesenchymal stem cells (hUC-MSCs), obtained hUC-MSCs were induced by 20% follicular fluid according to the method that has been proved by the researchers’ previous studies. Results showed that hUC-MSCs differentiated into oocyte-like structures and expressed germ cell makers. [Cell Biochem Funct] Abstract

    Enhancement of Wound Closure in Diabetic Mice by Ex Vivo Expanded Cord Blood CD34+ Cells
    Researchers investigated the influence on wound closure of treatments using expanded human cord blood CD34+ cells (CB-CD34+ cells), freshly isolated CB-CD34+ cells and a cytokine cocktail. [Cell Mol Biol Lett] Abstract

    StemSpan ACF: The WORLD'S FIRST Plasma Component-Free Hematopoietic Expansion Medium. Come learn more.

    REVIEWS
    Umbilical Cord Blood Transplantation: The First 25 Years and Beyond
    Umbilical cord blood is an alternative hematopoietic stem cell source for patients with hematologic diseases who can be cured by allogeneic hematopoietic cell transplantation. The growth of the field over the last 25 years and the plans for future exploration are discussed. [Blood] Abstract

    Visit our reviews page to see a complete list of reviews in the cord blood research field.

    SMi's Cell Culture Conference July 3-4, 2013 in London, United Kingdom

    INDUSTRY NEWS

    NeoStem’s Subsidiary, Progenitor Cell Therapy, to Provide Autologous and Allogeneic Cellular Therapy Services to MedStar Georgetown University Hospital
    NeoStem, Inc. and its subsidiary, Progenitor Cell Therapy, LLC (PCT) announced that PCT has entered into a Cell Therapy Processing Customer Agreement with MedStar Georgetown University Hospital to provide autologous and allogeneic cellular therapy services for cellular products provided by MedStar Georgetown University Hospital (MGUH) and deliver resulting cellular therapy products to MGUH for patient care. [NeoStem, Inc.] Press Release

    Pioneering Researchers Recognized for Scientific Achievements in Gene and Cell Therapy
    The American Society of Gene & Cell Therapy (ASGCT) is honored to recognize Dr. Sonia Skarlatos, PhD, and Dr. Catherine McKeon, PhD as the recipients of the Distinguished Service Award. This award recognizes an ASGCT Member or group that has consistently fostered and enhanced the field of genetic and cellular therapy. [American Society of Gene & Cell Therapy] Press Release

    From our sponsor:
    View immunology lectures, protocols and other resources on the Human Immunology Portal.

    POLICY NEWS

    National Institutes of Health (United States)

    Food and Drug Administration (United States)

    Center for Biologics Evaluation and Research (United States)

    European Medicines Agency (European Union)

    Medicines and Healthcare Products Regulatory Agency (United Kingdom)

    Therapeutic Goods Administration (Australia)

    EVENTS

    EVENT SPONSOR MSC 2013 – Adult Stem Cell Therapy & Regenerative Medicine

    MSC 2013 will offer a forum for the exchange and discussion of research, ideas, and cutting-edge breakthroughs in translational regenerative medicine.

    August 19-21, 2013
    Cleveland, United States

    Visit our events page to see a complete list of events in the cord blood community.

    JOB OPPORTUNITIES

    NEW Assistant Professor – Stem Cell Transplantation (Boston Children’s Hospital/Harvard Medical School)

    Postdoctoral Fellow – Stem Cell and Cancer Biology (Johns Hopkins University School of Medicine)

    Postdoctoral Research Scientist (Anthony Nolan)

    Research Associate (University of Texas Southwestern Medical Center at Dallas)

    Postdoctoral Position – Novel Gene Discovery (St. Jude Children’s Research Hospital)

    Postdoctoral Position – Stem Cell Biology (St. Jude Children’s Research Hospital)

    Technology Manager (GE Healthcare)

    Development/Senior Development Scientist (GE Healthcare)


    Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

    Have we missed an important article or publication in Cord Blood News? Click here to submit!

    Comments or Suggestions? Email info@connexoncreative.com with your feedback.

    Learn more about Cord Blood News: Archives | Events | Contact Us